Abstract
Mesenchymal stem cells (MSCs) from post-natal bone marrow possess tremendous potential for cell-mediated gene therapy in several disease processes, and recent reports have broadened the spectrum for therapeutic applications to cancer therapy. The evidence that sites of active tumorigenesis favor the homing of exogenous MSCs have support the rationale for developing engineered MSCs as a tool to track malignant tissues and deliver anticancer agents within the tumor microenvironment. Several reports have proven the efficiency of MSCs as cell carrier for in vivo delivery of various clinically relevant anticancer factors, including cytokines, interferon, pro-drugs or replicative adenovirus, and tumor growth inhibition following engraftment within or in the vicinity of tumor. The enthusiasm for MSCs is further reinforced by the striking observation that unmodified MSCs can exert antitumorigenic activity, and preliminary reports in immunocompetent animals have provided encouraging results for the use of MSCs in cancer immunotherapy. This review highlights recent works and potential clinical applications of MSCs in this field.
Keywords: Mesenchymal stem cells, bone-marrow, cell-mediated gene therapy, migration, tumor-tropism, cancer therapy
Current Stem Cell Research & Therapy
Title: Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Volume: 3 Issue: 1
Author(s): Vanessa Fritz and Christian Jorgensen
Affiliation:
Keywords: Mesenchymal stem cells, bone-marrow, cell-mediated gene therapy, migration, tumor-tropism, cancer therapy
Abstract: Mesenchymal stem cells (MSCs) from post-natal bone marrow possess tremendous potential for cell-mediated gene therapy in several disease processes, and recent reports have broadened the spectrum for therapeutic applications to cancer therapy. The evidence that sites of active tumorigenesis favor the homing of exogenous MSCs have support the rationale for developing engineered MSCs as a tool to track malignant tissues and deliver anticancer agents within the tumor microenvironment. Several reports have proven the efficiency of MSCs as cell carrier for in vivo delivery of various clinically relevant anticancer factors, including cytokines, interferon, pro-drugs or replicative adenovirus, and tumor growth inhibition following engraftment within or in the vicinity of tumor. The enthusiasm for MSCs is further reinforced by the striking observation that unmodified MSCs can exert antitumorigenic activity, and preliminary reports in immunocompetent animals have provided encouraging results for the use of MSCs in cancer immunotherapy. This review highlights recent works and potential clinical applications of MSCs in this field.
Export Options
About this article
Cite this article as:
Fritz Vanessa and Jorgensen Christian, Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy, Current Stem Cell Research & Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488808783489462
DOI https://dx.doi.org/10.2174/157488808783489462 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Lipid Based Anti-Retroviral Nanocarriers: A Review of Current Literature and Ongoing Studies
Drug Delivery Letters A Brief Review of the Essential Role of Nanovehicles for Improving the Therapeutic Efficacy of Pharmacological Agents Against Tumours
Current Drug Delivery The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Microarray Data Analysis to Find Diagnostic Approach and Identify Families of Disease-Altered Genes Based on Rank-Reverse of Gene Expression
Current Bioinformatics Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Current Topics in Medicinal Chemistry Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Anti-Toxoplasma Activity of Natural Products: A Review
Recent Patents on Anti-Infective Drug Discovery